Michael Forsyth

Cost Effectiveness of Evidence-Based Treatment Guidelines for the Treatment of Non–Small-Cell Lung Cancer in the Community Setting

Marcus A. Neubauer, J. Russell Hoverman, Michael Kolodziej et al. · Journal of Oncology Practice · 2010 · 173 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +13

Survival Outcomes of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Treated in US Community Oncology

Thomas H. Cartwright, Yeun Mi Yim, Elaine Yu et al. · Clinical Colorectal Cancer · 2012 · 39 citations

Medicine, Oncology, Pharmacotherapy +10

Evaluating Use Characteristics for the Onco<i>type</i> Dx 21-Gene Recurrence Score and Concordance With Chemotherapy Use in Early-Stage Breast Cancer

Clara Chen, Rahul Dhanda, Wan-Yu Tseng et al. · Journal of Oncology Practice · 2013 · 37 citations · Full text

Medicine, Oncology, Breast Oncology +6

Bevacizumab Treatment to Progression After Chemotherapy: Outcomes from a U.S. Community Practice Network

Eric Nadler, Elaine Yu, Arliene Ravelo et al. · The Oncologist · 2011 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Dosing Patterns, Toxicity, and Outcomes in Patients Treated With First-Line Sunitinib for Advanced Renal Cell Carcinoma in Community-Based Practices

Ian D. Schnadig, Thomas E. Hutson, Hsingwen Chung et al. · Clinical Genitourinary Cancer · 2014 · 21 citations

Medicine, Oncology, Pharmacology +13